Our CEO Emanuele Ostuni is participating in a fireside chat today at the 2nd Annual TD Cowen Radiopharmaceutical Innovation Summit, where he will share ARTBIO’s latest news and shine a spotlight on our end-to-end approach to building a #manufacturing network and further developing our pipeline. More information on how ARTBIO is advancing #radiopharmaceutical development through our unique approach to #alpha #radioligand #therapy (ART) can be explored on our website: https://artbio.com/#about #RLT #biotech #Pb212
ARTBIO’s Post
More Relevant Posts
-
Starting a biologic or other targeted medicine? Take a look at our newly redeveloped information to find out what to expect from these treatments, which can help control Crohn’s and Colitis. Our new information on biologics and other targeted medicines covers what they are, how they work, who might take them and more. Click the link for more information: https://ow.ly/kx3b50PY8LU
To view or add a comment, sign in
-
-
Brilliant article from Crohn's & Colitis UK re the use of biologics and how they work My husband has previously been on Infliximab and now on Ustekinumab 🤞 Knowledge is power when it comes to living with IBD! Take a look 👀
Starting a biologic or other targeted medicine? Take a look at our newly redeveloped information to find out what to expect from these treatments, which can help control Crohn’s and Colitis. Our new information on biologics and other targeted medicines covers what they are, how they work, who might take them and more. Click the link for more information: https://ow.ly/kx3b50PY8LU
To view or add a comment, sign in
-
-
Navigating a successful launch amid rising costs and fierce competition poses challenges for new pharma brands. 🚀 Check out our latest article for insights on overcoming these hurdles!
Fewer than one in ten compounds in the preclinical phase make it to the market, and once there, the average revenue per drug has declined significantly. With the average development cost in pharma soaring and the increasing difficulty in differentiation, launching a new therapy is undoubtedly a challenge. Learn how to navigate the complexity of launches in our latest paper: https://loom.ly/3cQ4gBo #pharma #therapy #launch
To view or add a comment, sign in
-
-
Fewer than one in ten compounds in the preclinical phase make it to the market, and once there, the average revenue per drug has declined significantly. With the average development cost in pharma soaring and the increasing difficulty in differentiation, launching a new therapy is undoubtedly a challenge. Learn how to navigate the complexity of launches in our latest paper: https://loom.ly/3cQ4gBo #pharma #therapy #launch
To view or add a comment, sign in
-
-
The challenges of launching a new therapy are significant, with high development costs and increasing competition in the market. Overcoming regulatory barriers, educating healthcare providers, and building awareness are key steps to a successful launch. However, with the increasing number of treatment options available in disease areas, differentiation and meeting forecasts have become more difficult. Understanding, positioning, and preparing for a launch are crucial steps to overcome these challenges and achieve success in the market. Learn more in our latest article!
Fewer than one in ten compounds in the preclinical phase make it to the market, and once there, the average revenue per drug has declined significantly. With the average development cost in pharma soaring and the increasing difficulty in differentiation, launching a new therapy is undoubtedly a challenge. Learn how to navigate the complexity of launches in our latest paper: https://loom.ly/3cQ4gBo #pharma #therapy #launch
To view or add a comment, sign in
-
-
Learn how to navigate the complexity of launches in our latest paper 🚀 💉
Fewer than one in ten compounds in the preclinical phase make it to the market, and once there, the average revenue per drug has declined significantly. With the average development cost in pharma soaring and the increasing difficulty in differentiation, launching a new therapy is undoubtedly a challenge. Learn how to navigate the complexity of launches in our latest paper: https://loom.ly/3cQ4gBo #pharma #therapy #launch
To view or add a comment, sign in
-
-
How to succeed in environment that is throwing challenges and barriers at you? That's essentially what your key business question is when you are involved in the #launch of a new #pharma product. Despite the numberous pitfalls in launch, creating #differentiation and having solid #benchmarks are two fundamental boxes to tick in this process. Want to learn more? Read this insightful article from Trilations Healthcare Strategies or reach out to me personally!
Fewer than one in ten compounds in the preclinical phase make it to the market, and once there, the average revenue per drug has declined significantly. With the average development cost in pharma soaring and the increasing difficulty in differentiation, launching a new therapy is undoubtedly a challenge. Learn how to navigate the complexity of launches in our latest paper: https://loom.ly/3cQ4gBo #pharma #therapy #launch
To view or add a comment, sign in
-
-
It is imperative to stay competitive in a crowded and undifferentiated market. By comparing against industry benchmarks, pharmaceutical companies can identify areas for improvement and better position their launching brands. This helps in making more informed strategic decisions.
Fewer than one in ten compounds in the preclinical phase make it to the market, and once there, the average revenue per drug has declined significantly. With the average development cost in pharma soaring and the increasing difficulty in differentiation, launching a new therapy is undoubtedly a challenge. Learn how to navigate the complexity of launches in our latest paper: https://loom.ly/3cQ4gBo #pharma #therapy #launch
To view or add a comment, sign in
-
-
🤔 Do you know what is the purpose of drug delivery systems? The purpose of drug delivery systems is to safely, effectively, and efficiently deliver therapeutic agents to specific target sites in the body, achieving optimal therapeutic outcomes. 🎯 Drug delivery systems go one step further than just delivering pharmaceuticals to their target location, they are engineered systems that can address specific challenges associated with drug pharmacokinetics and pharmacodynamics. 🚀 Nanocarriers, like lipidic nanosystems, improve molecules' poor bioavailability and limited passage through the body's natural barriers, like the blood-brain barrier or cellular membranes. Do you want to find out how? Check out our latest blog 👇🏼 (https://lnkd.in/gMmbzPGR) #drugdelivery #nanoparticles #nanotechnology #nanomedicine
To view or add a comment, sign in
Innovative Leadership in Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies.
4wExciting news from ARTBIO! 🔬🌟 CEO Emanuele Ostuni's fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit promises to shed light on ARTBIO’s innovative strides in alpha radioligand therapy. Your end-to-end manufacturing network and pipeline development are truly paving the way in radiopharmaceuticals. Looking forward to hearing more about your groundbreaking advancements!